Printer Friendly

BIOCHEM PHARMA ISSUES STATEMENT ON STOCK ACTIVITY

 BIOCHEM PHARMA ISSUES STATEMENT ON STOCK ACTIVITY
 LAVAL, Quebec, April 29 /PRNewswire/ -- BioChem Pharma Inc.


(NASDAQ: BCHXF) today announced it is aware of no reason related to its business that would explain the unusual activity in the company's share price. BioChem confirms its intention to proceed with its proposed public offering of up to 3.5 million common shares.
 The public offering will be underwritten in the United States by a syndicate of underwriters led by Morgan Stanley & Co. Incorporated and Tucker Anthony Incorporated and outside the United States by Kleinwort Benson Limited and Morgan Stanley International and a syndicate of banks. The underwriters plan to offer the shares in late May 1992.
 Copies of the preliminary prospectus relating to the U.S. offering may be obtained from Morgan Stanley & Co. Incorporated, 1251 Avenue of the Americas, New York, NY 10020, and Tucker Anthony Incorporated, One World Financial Center, 200 Liberty St., 3rd floor, New York, NY 10281. Copies of the preliminary prospectus relating to the U.K. and European offering may be obtained from Kleinwort Benson Limited, 20 Fenchurch St., London EC3P 3DB, to the attention: Nigel Brassard.
 BioChem Pharma Inc. is engaged in the research and development of therapeutic products and the research, development, manufacturing and marketing of vaccine and diagnostic products for a broad range of infectious and other diseases. The company's shares are listed on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ stock market (BCHXF). In addition, following discussions with the London Stock Exchange, the company expects its common shares to be listed following the offering.
 A registration statement relating to these shares has been filed with the Securities and Exchange Commission but has not yet become effective. These shares may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The shares will not be offered for sale to the public in Canada. This news release shall not constitute an offer to sell or the solicitation of an offer to buy. Nor shall there be any sale of these securities in any state in which such offer or solicitation of sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 -0- 4/29/92
 /CONTACT: Francesco Bellini of BioChem Pharma, 514-681-1744/
 (BCHXF) CO: BioChem Pharma Inc. ST: Quebec IN: MTC SU:


TQ-GK -- NY068 -- 4497 04/29/92 15:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:405
Previous Article:NEWS CONFERENCE SET FOR THURSDAY REGARDING CONSTRUCTION OF BICYCLIST/HIKER TRAIL AROUND BWI AIRPORT
Next Article:WILLCOX & GIBBS POSTS 58 PERCENT GAIN IN FIRST QUARTER PROFITS


Related Articles
IAF BIOCHEM INTERNATIONAL BECOMES BIOCHEM PHARMA
BIOCHEM PHARMA DOUBLES ITS REVENUES IN FIRST QUARTER
BIOCHEM GETS ANOTHER MAJOR SALES CONTRACT IN EUROPE
1992-1993 FISCAL YEAR: BIOCHEM PHARMA MAINTAINS SOLID FINANCIAL POSITION
BIOCHEM PHARMA: INTERIM DATA FROM PHASE I/II 3TC TRIALS PRESENTED AT MONTREAL HIV MEETING
BIOCHEM IS STILL GROWING
BIOCHEM IS STILL GROWING
LAMIVUDINE: EARLY PHASE II TRIAL RESULTS ENCOURAGING; LATE PHASE II TRIALS INITIATED
U.S. JUDGE GRANTS BIOCHEM'S MOTION TO STAY 3TC PATENT CASE
Biochem Acquires Class A Common Shares of Clinichem Held by Glaxo.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters